At a glance
- Originator Kyowa Hakko
- Class
- Mechanism of Action Cholestenone 5 alpha-reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Benign prostatic hyperplasia
Most Recent Events
- 01 Feb 2000 No-Development-Reported for Benign prostatic hyperplasia in Japan (Unknown route)
- 20 Feb 1997 New profile
- 20 Feb 1997 Preclinical development for Benign prostatic hyperplasia in Japan (Unknown route)